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Available online 6 May 2016Fanconi Anemia (FA) is a genetic disorder characterized by elevated cancer susceptibility and pro-inﬂammatory
cytokine production. Using SLX4FANCP deﬁciency as a working model, we questioned the trigger for chronic in-
ﬂammation in FA. We found that absence of SLX4 caused cytoplasmic DNA accumulation, including sequences
deriving fromactive Long INterspersed Element-1 (LINE-1), triggering the cGAS-STINGpathway to elicit interfer-
on (IFN) expression. In agreement, absence of SLX4 leads to upregulated LINE-1 retrotransposition. Importantly,
similar results were obtained with the FANCD2 upstream activator of SLX4. Furthermore, treatment of FA cells
with the Tenofovir reverse transcriptase inhibitor (RTi), that prevents endogenous retrotransposition, decreased
both accumulation of cytoplasmic DNA andpro-inﬂammatory signaling. Collectively, our data suggest a contribu-
tion of endogenous RT activities to the generation of immunogenic cytoplasmic nucleic acids responsible for in-
ﬂammation in FA. The additional observation that RTi decreased pro-inﬂammatory cytokine production induced
by DNA replication stress-inducing drugs further demonstrates the contribution of endogenous RTs to sustaining
chronic inﬂammation. Altogether, our data open perspectives in the prevention of adverse effects of chronic in-
ﬂammation in tumorigenesis.











Fanconi Anemia (FA) is a rare autosomal recessive genetic disorder
caused by bi-allelic mutations in any of the 17 identiﬁed FA comple-
mentation group genes that compose the FA DNA repair pathway
(Wang and Smogorzewska, 2015). FA is characterized by elevated
pro-inﬂammatory cytokine levels, heightened cancer susceptibility, se-
vere developmental defects and progressive bone marrow failure
(Bogliolo and Surralles, 2015). Recent work has shown that the
SLX4FANCP effector of the FA DNA repair pathway, is directly involved
in regulating pathogen-induced cytokine production (Laguette et al.,
2014). Indeed, SLX4 assembles several proteins involved in DNAmetab-
olism, into a complex (SLX4com) involved in the repair of double strand
breaks (Matos andWest, 2014), but also likely acts on incoming patho-
gen-associated nucleic acids to favor their clearance (Laguette et al.,
2014) preventing innate immune sensing. Furthermore, spontaneous
production of pro-inﬂammatory cytokines by FA cells (Du et al., 2014;
Dufour et al., 2003; Laguette et al., 2014) also raises the hypothesisenkirane),
. This is an open access article underthat this DNA repair pathway may be required for the processing of im-
munogenic endogenous nucleic acids.
Accordingly, besides their role in DNA repair, a direct role of DNA
damage response (DDR) proteins in the control of spontaneous and
pathogen-induced pro-inﬂammatory cytokine production has recently
emerged (Bregnard et al., 2014; Hartlova et al., 2015). It has been
shown that DDR proteins can either detect non-canonical endogenous
and pathogen-derived nucleic acids to trigger the production of pro-in-
ﬂammatory cytokines, including antiviral interferons (IFN) (Ferguson et
al., 2012; Kondo et al., 2013; Zhang et al., 2011), or promote their deg-
radation and prevent recognition by the innate immune system
(Laguette et al., 2014; Stetson et al., 2008; Yan et al., 2010). In agree-
ment, persistent genomic lesions have been linked to elevated pro-in-
ﬂammatory cytokine production (Bald et al., 2014; Brzostek-Racine et
al., 2011).
Recent reports also show that cancer cells present with cytoplasmic
nucleic acids that trigger the production of type I IFN (Hartlova et al.,
2015; Koo et al., 2015; Shen et al., 2015). Recognition of these nucleic
acids relies on pattern recognition receptors that converge on adaptor
proteins to ensure activation of transcription factors such as NF-κB
and interferon regulatory factor (IRF) 3 and IRF7 to produce IFN and ad-
ditional pro-inﬂammatory cytokines (Paludan, 2015). Detection of cyto-
plasmic DNA leads to the activation of the adaptor protein stimulator ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
185C. Brégnard et al. / EBioMedicine 8 (2016) 184–194interferon genes (STING) upon activation of sensor proteins like Cyclic
GMP-AMP synthase (cGAS) or Gamma-interferon-inducible protein
iﬁ-16 (IFI16) (Ishikawa and Barber, 2008; Ishikawa et al., 2009), while
extracellular nucleic acids are detected by Toll-Like Receptors (TLRs)
that reside on intracellular organelles such as endosomes, leading to
the activation of myeloid differentiation primary response gene 88
(MYD88) or TIR-domain-containing adaptor-inducing interferon-β
(TRIF) (Rakoff-Nahoum and Medzhitov, 2009). While the origin of en-
dogenous immunogenic nucleic acids is still debated, there are indica-
tions that they are generated in the nucleus (Hartlova et al., 2015;
Yang et al., 2007) and are, at least in part, comprised of DNA repair
by-products (Rigby et al., 2014; Shen et al., 2015). Interestingly, absence
of DDR proteins can lead to upregulated retrotransposition (Stetson et
al., 2008), which constitutes a potential source of immunogenic endog-
enous nucleic acids. Indeed, a subfamily of Long INterspersed Element-1
(LINE-1), retains the ability to retrotranspose autonomously and re-in-
sert at distant genomic locations (Babushok and Kazazian, 2007;
Kazazian et al., 1988). In addition, de-repression of LINE-1 elements
has been documented in a range of inﬂammatory and autoimmune dis-
eases (Volkman and Stetson, 2014) associated with mutations in genes
involved in the metabolism of nucleic acids, including genomic lesions
and incoming pathogen-derived nucleic acids (Gasior et al., 2008;
Stetson et al., 2008). However, how upregulated LINE-1 activity may
lead to induction and persistence of pro-inﬂammatory signals remains
to be investigated.
Here, we wished to identify the trigger for spontaneous pro-inﬂam-
matory cytokine production in FA. We used SLX4 deﬁciency as a work-
ing model, because we previously identiﬁed a role for SLX4-associated
nuclease activities in repressing HIV-mediated pro-inﬂammatory sig-
naling (Laguette et al., 2014). We reveal that SLX4-deﬁcient cells pres-
ent cytoplasmic DNA that is recognized by the cGAS-STING pathway
to activate IFN signaling. We further establish that these cytoplasmic
nucleic acids are, at least in part, generated by upregulated LINE-1 activ-
ity. Accordingly, treatment with Tenofovir, a nucleoside analogue re-
verse-transcriptase (RT) inhibitor that can prevent endogenous RT
activities, leads to decreased cytoplasmic LINE-1-derived nucleic acids
and pro-inﬂammatory cytokine levels. Finally, we also show that treat-
ment with Tenofovir prevents chemotherapy-induced inﬂammation.
Altogether, by establishing a link between upregulated endogenous RT
activities and spontaneous pro-inﬂammatory cytokine production in
SLX4 deﬁciency, our ﬁndings open perspectives in preventing pervasive
pro-inﬂammatory signaling in the FA cancer susceptibility syndrome
and chemotherapy.
2. Materials and Methods
For detailed experimental procedures see Supplementary material.
2.1. Cell Lines and Plasmids
RA3331- and PD20-derived cell lines were kind gifts from Dr.
Smogorzewska and Dr. Rosselli respectively. The A549 IFN-responsive
cell line (Chen et al., 2010) was obtained from Dr. Goodbourn.
pCEP-UB_LRE3_GFPi (LINE-1 GFP), pAD2TE1 (LINE-1NEORT+) and
pAD135 (LINE-1 NEO RT-) were gifts from Dr. Gilbert (Doucet et al.,
2010; Wei et al., 2001). pYX017 (LINE-1 LUC RT+) and pYX015
(LINE-1 LUC ORF1mut) were kindly provided by Dr. A n (Xie et al.,
2011).
2.2. Cytoplasmic and Nuclear DNA Extraction and Analysis
All steps were performed at 4 °C except otherwisementioned. Cyto-
plasmic and nuclear fractions were extracted from equal amounts of
cells. Cells were lysed in low salt lysis buffer (100mMNaCl; 10% glycer-
ol; 0.1% Triton; 20 mM Tris [pH 7.5]; 2 mM MgCl2; 0.5 mM EDTA;
0.2 mM PMSF; 10 mM β-mercaptoethanol) for 20 min on wheel,followed by 10min centrifugation at 4000 rpm. The supernatant, corre-
sponding to the cytoplasmic fraction,was collectedwhile the remaining
pellet was further extracted with high salt lysis buffer (340 mM NaCl;
10% glycerol; 0.1% Triton; 20 mM Tris [pH 7.5]; 2 mM MgCl2; 0.5 mM
EDTA; 0.2 mM PMSF; 10 mM β-mercaptoethanol) for 30 min on
wheel, followed by 30 min centrifugation at 13,200 rpm. The superna-
tant, corresponding to the soluble nuclear fraction, was collected. Cyto-
plasmic and nuclear fractions were assessed by WB and further treated
or not with RNase cocktail (RNase A 5 U/ml, RNase T1 200 U/ml;
Ambion) for 30 min at 37 °C and Proteinase K (200 μg/ml; Ambion)
for 2 h at 50 °C prior to DNA extraction using Phenol/Chloroform/
Isoamyl pH 8 (12/12/1).
For qPCR analysis using LINE-1-speciﬁc primers, results were nor-
malized on Cytochrome B levels and Genomic DNA contamination. Ac-
tive LINE-1 sequences were identiﬁed using primers described by
Boissinot et al. (2000). To sequence cytosolic DNA from RA3331 cells,
PCR products were cloned into the TOPO Blunt Vector (ThermoFisher
Scientiﬁc). Analysis of sequences was performed using a consensus
LINE-1 sequence (m80343 clone; NCBI).
For radiolabeling experiments, the DNA was dephosphorylated
using rSAP (NEB) prior to labeling with γ32P ATP for 30 min at 37 °C
using the T4 Polynucleotide kinase (NEB). Subsequent S1 Nuclease,
dsDNase and RNaseH (ThermoFisher Scientiﬁc) treatments were per-
formed following the manufacturer's protocol. Unbound radiolabeled
nucleotides were removed using Illustra Microspin G-50 Columns (GE
Healthcare) prior to resolution on 5% acrylamide, 0.5% Tris Borate
Ethylamide gel and autoradiography.
Southern Blot analysis using a LINE-1-speciﬁc probe was performed
following resolution on 1.3% agarose gels. The probe was generated
using the pYX017 plasmid and labeled using the Prime-a-Gene Labeling
System (Promega) according to the manufacturer's protocol.
2.3. RNA Extraction and RT-qPCR
RNA was extracted using Trizol (Invitrogen) and treated with
TURBO DNase (Ambion) according to the manufacturers' protocol. Re-
verse transcription (SuperSriptIII reverse transcriptase; Invitrogen)
and qPCR (QIAGEN) using speciﬁc primers were performed using stan-
dard protocols.
2.4. Immunoprecipitation
293T cells were transfected with indicated plasmids using the calci-
um phosphate method. Forty-eight hours post-transfection, cells were
lysed in 10 cell pellet volumes of buffer (20 mM Tris-HCl [pH 7.5],
0.5 mM EDTA, 150 mM NaCl, 10 mM KCl, 0.5% Triton, 1.5 mM MgCl2,
10% glycerol, 10 mM; 0.2 mM PMSF; 10 mM β-mercaptoethanol)
30 min at 4 °C on wheel, followed by 30 min of centrifugation at
13,200 rpm. Whole-cell extracts were incubated with anti-FLAG beads
(Sigma-Aldrich) and immunoprecipitates eluted using an excess of
FLAG peptide followed by WB or DNA content analysis. For DNA-IP,
DNA from input and eluates were extracted using Phenol/Chloroform/
Isoamyl pH 8 (12/12/1). qPCR analysis was performed using speciﬁc
primers and data normalized for input DNA. Disruption of protein/
nucleic acid interactions was achieved by preparing whole cell extracts
in the presence of 0.1 mg/ml Ethidium Bromide (Sigma-Aldrich) and
0.1 U/μl DNaseI (Sigma-Aldrich).
2.5. Retrotransposition Assay
After siRNA transfection or SLX4 overexpression, cells were
transfected with LINE-1 reporter plasmids using the FuGene-6 transfec-
tion reagent (Promega). In cases where neomycin reporter plasmids
were used, cells were grown in the presence of G418 (600 μg/ml) for
18 days prior to ﬁxation with 3.2% paraformaldehyde and crystal violet
staining. For dual luciferase retrotransposition assays, luminescence
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porter Assay System (Promega), following the manufacturer's
instructions.
2.6. Analysis of Interferon Secretion
RA3331SLX4 cells were grown for 48 h in the presence of conditioned
medium from RA3331 and RA3331SLX4, pre-incubated or not with IFNα,
IFNβ (pbl assay science) and IFNγ neutralizing antibody (Abcam) for
2 h. A549 cells were treated with conditioned medium from RA3331,
RA3331SLX4 or RA3331SLX4ΔSAP for 24 h. IFN response was measured by
RT-qPCR.
2.7. Immunoﬂuorescence
Cells were seeded on ﬁbronectin-coated coverslips (Sigma-Aldrich).
Fixation was performed in 80% methanol followed by 1 h blocking in
PBS, 0.1% Tween, 1% BSA. ssDNA was visualized using anti-ssDNA
(Abcam) at 1:50 dilution in PBS, 0.1% Tween, 1% BSA followed by incu-
bation with anti-mouse Alexa 488-conjugated secondary antibody (Life
Technologies). When indicated, S1 Nuclease digestion was performed
before ssDNA staining. Nuclei were stained with DAPI and images
were collected on Leica DM6000 or Zeiss Apotome microscopes.
3. Results
3.1. Accumulation of Cytoplasmic ssDNA Leads to Interferon Production in
SLX4 Deﬁciency
We previously reported (Laguette et al., 2014) that absence of SLX4
and of MUS81 both lead to upregulated type I IFN (IFNα and IFNβ) and
IFN stimulated gene (MxA) mRNA expression. Here, we wished to de-
termine whether the control of spontaneous pro-inﬂammatory cyto-
kine production by SLX4 and MUS81 results from independent
activities or a coordinated activity within the SLX4com. To this aim,
we used the previously described cell lines derived from SLX4-deﬁcient
FA patient cells, complemented with either an empty vector (RA3331),
a WT-SLX4 allele (RA3331SLX4), or a SLX4 allele harboring a deletion of
the SAP domain (SLX4ΔSAP) responsible for interaction with MUS81-
EME1 (RA3331SLX4ΔSAP) (Kim et al., 2013). This SLX4 construct is im-
paired in its ability to interact with MUS81-EME1 but can still bind
other SLX4 partners, including ERCC4 (Fig. S1A and (Kim et al., 2013)).
Accordingly, RA3331SLX4ΔSAP cells present elevated sensitivity to drugs
that cause replication fork collapse, but not to DNA crosslinking agents
such as Mitomycin C (MMC) (Kim et al., 2013). Measuring type I, type
II IFN and MxA mRNA levels by RT-qPCR showed spontaneous produc-
tion in RA3331 cells that was prevented by expression of SLX4, but
not of SLX4ΔSAP (Fig. 1A). Additional Interferon Stimulated Genes
(ISGs) were also found to be upregulated in RA3331, and
RA3331SLX4ΔSAP (Fig. S1B). Of note, WT SLX4 expression was more efﬁ-
cient at decreasing the expression of some tested ISGs, indicating a po-
tential contribution of additional SLX4 domains in the control of pro-
inﬂammatory signals. Consistently, analysis of protein levels of IRF7,
IRF3 and of the phosphorylated active form of IRF3 (pIRF3) byWestern
Blot (WB) reveals an accumulation of IRF7 and pIRF3 in RA3331 and
RA3331SLX4ΔSAP as compared to RA3331SLX4 (Fig. 1B). To investigate
whether upregulation of IFN mRNA expression results in bona ﬁde se-
cretion of cytokines, experiments were performed where RA3331SLX4
cells treated with conditioned media from RA3331 displayed increased
type I and type II IFN mRNA levels as compared to cells treated with
media collected from RA3331SLX4 (Fig. 1C). In addition, pre-incubating
conditioned medium from RA3331with human neutralizing antibodies
against IFNα, IFNβ and IFNγ prevented the measured increase of IFN
mRNA (Fig. 1C). This is further conﬁrmed by cultivating the A549 IFN-
responsive cell line in the presence of conditioned medium collected
from RA3331, RA3331SLX4, and RA3331SLX4ΔSAP showing thatconditioned media from RA3331 and RA3331SLX4ΔSAP but not
RA3331SLX4 induced upregulation of MxA mRNA levels (Fig. S1C). This,
together with previous observation that MUS81 depletion leads to up-
regulation of pro-inﬂammatory cytokines (Laguette et al., 2014),
strongly suggests that recruitment of MUS81-EME1 to SLX4 is required
for SLX4com-mediated repression of pro-inﬂammatory pathways.
Because the SLX4com processes HIV-derived nucleic acids (Laguette
et al., 2014), preventing its innate immune sensing, and absence of SLX4
leads to activation of pattern recognition pathways (Fig. S1B), we hy-
pothesized that SLX4-associated nuclease activities may be involved in
processing endogenous nucleic acids to avoid spontaneous pro-inﬂam-
matory cytokine production. Consequently, absence of SLX4 should lead
to accumulation of cytoplasmic immunogenic nucleic acids. To test this
hypothesis, we performed immunoﬂuorescence staining of RA3331,
RA3331SLX4 and RA3331SLX4ΔSAP cells using a ssDNA-speciﬁc antibody
(Fig. 2A–B). Enrichment in cytoplasmic staining was observed in
RA3331 and RA3331SLX4ΔSAP cells but not in RA3331SLX4 cells. Addition-
ally, absence of MUS81 in mouse embryonic ﬁbroblasts (MEFMUS81−/−)
also led to accumulation of cytosolic ssDNA as compared to WT MEFs
(Fig. S2A). This shows that lack of SLX4 results in accumulation of cyto-
solic ssDNA and highlights the requirement of MUS81 binding to SLX4
for cytosolic DNA clearance. Of note, treatment with the S1 Nuclease
that preferentially digests ssDNA, caused a net decrease of the observed
cytoplasmic staining (Fig. S2B).
Since it has been previously reported that the cytoplasm of cancer
cells contains a mix of ssDNA, dsDNA and DNA:RNA hybrids (Koo et
al., 2015; Shen et al., 2015), we questioned the nature of the nucleic
acids present in the cytoplasm of SLX4-deﬁcient cells. To this aim,
γP32-labeling of cytoplasmic DNA from RA3331, RA3331SLX4 and
RA3331SLX4ΔSAP cells was performed (Fig. 2C, left panel). Cytoplasmic
and nuclear extracts were analyzed byWB to check for nuclear contam-
ination of cytoplasmic fraction (Fig. S2C). Autoradiography revealed in-
creased presence of nucleic acids in the cytoplasmic fraction of RA3331
and RA3331SLX4ΔSAP as compared to RA3331SLX4 (Fig. 2C, right panel).
Importantly, treatment of the material obtained from RA3331 and
RA3331SLX4ΔSAP cells with S1 Nuclease leads to reduction of the signal
(Fig. 2C and S2D) conﬁrming the presence of ssDNA in the cytoplasm
of SLX4-deﬁcient cells. Similarly, treatment with dsDNAse or RNaseH,
led to decreased levels of cytoplasmic nucleic acid in RA3331 and
RA3331SLX4ΔSAP (Fig. S2E and S2F), indicating that the cytosol of SLX4-
deﬁcient cells contains dsDNA, ssDNA and DNA:RNA hybrids and that
SLX4-MUS81 interaction is required to prevent their accumulation. Of
note, it has been reported that immunogenic nucleic acids present in
the cytoplasm of cancer cells are generated in the nucleus (Hartlova et
al., 2015; Yang et al., 2007). Interestingly, radiolabeling experiments of
DNA extracted from the soluble nuclear fraction of RA3331,
RA3331SLX4 and RA3331SLX4ΔSAP, followed by digestionwith S1 Nuclease
(Fig. S2G) shows the presence of ssDNA in the nuclear fraction of
RA3331 and RA3331SLX4ΔSAP, but not RA3331SLX4.
To investigate whether the DNA species present in the cytoplasm of
RA3331 cells are responsible for IFN production, RA3331 cells were
engineered to stably express an inducible short hairpin RNA (shRNA)
targeting STING (TMEM173). To assess the contribution of extracellular
nucleic acids to the signaling pathway triggered in the absence of
SLX4, we also included shRNAs targetingMYD88 (Fig. 2D–F). As a con-
trol, RA3331 cells expressing an inducible shRNA targeting the Lucifer-
ase gene were also engineered. Following 6 days of shRNA induction,
IRF3 phosphorylation status was assessed in whole cell extracts
(WCE) (Fig. 2D), while knockdown efﬁciency (Fig. 2E), MxA and addi-
tional IFN-inducible genes mRNA levels (Fig. 2F) were measured by
RT-qPCR. Knockdown of STING but not MYD88 led to decreased pIRF3
and IFN signaling (Fig. 2D–F). This indicates that cytoplasmic DNA pres-
ent in SLX4 deﬁcient cells is sensed through the STING pathway to in-
duce IFN production. To investigate whether previously identiﬁed
nucleic acid sensors of the STING pathway are required for pro-inﬂam-
matory signaling in SLX4 deﬁciency, we engineered cells where cGAS or
Fig. 1. The SAP MUS81-EME1-interacting domain of SLX4 is required for repressing inﬂammatory signals. (A) IFNα, IFNβ, IFNγ and MxA mRNA levels were measured by RT-qPCR in
RA3331 cells complemented either with WT-SLX4 (RA3331SLX4) or SLX4ΔSAP (RA3331SLX4ΔSAP). Graphs present means (±SD) of triplicate measurement of 6 independent
experiments expressed as fold change in mRNA expression relative to RA3331SLX4. ****: p b 0.001; ***: p b 0.005; **: p b 0.01. (B) WCE from RA3331, RA3331SLX4 and RA3331SLX4ΔSAP
were analyzed by WB using indicated antibodies. (C) IFNα, IFNβ and IFNγmRNA levels were measured in RA3331SLX4 treated with conditioned medium from RA3331SLX4 or RA3331
pre-incubated or not with neutralizing antibody to human IFNα, IFNβ and IFNγ. Graph represents mean (±SD) mRNA levels of one representative experiment relative to cells treated
with conditioned medium from RA3331SLX4. See also Fig. S1.
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the levels of pIRF3 and phosphorylated active TBK1 kinase (pTBK1),
known to be recruited by STING, by WB and of MxA by RT-qPCR (Fig.
2G–H). Knockdown efﬁciency was assessed by RT-qPCR (Fig. 2H). Si-
lencing cGAS but not IFI16 led to decreased pro-inﬂammatory signaling
(Fig. 2G) and MxA induction (2H), highlighting a role for the cGAS-
STING pathway in detecting cytosolic nucleic acids in SLX4-deﬁcient
cells. However, because of poor TRIF knockdown (not shown), we can-
not exclude a contribution of endosomal nucleic acids in the activation
of the inﬂammatory signal observed in SLX4-deﬁcient cells.
3.2. The SLX4 Complex Interacts With the LINE-1 Retrotansposition
Complex
We have shown that absence of SLX4 leads to HIV-derived DNA ac-
cumulation (Laguette et al., 2014), suggesting that SLX4-associated en-
donucleases are involved in processing the latter. This is reminiscent of
what has been reported for the TREX1 exonuclease (Yan et al., 2010).
Because TREX1 inhibits LINE-1 retrotransposition and cell-intrinsic ini-
tiation of autoimmunity (Stetson et al., 2008), we hypothesized that ab-
sence of SLX4 may similarly lead to LINE-1 deregulation, which could
account for subsequent cytoplasmic DNA accumulation. To test this hy-
pothesis, DNA was extracted from the cytoplasmic fraction of RA3331
and RA3331SLX4 (Fig. S3A). LINE-1 DNA was either quantiﬁed by qPCR(Fig. 3A) or visualized by Southern Blot (Fig. 3B). We thereby observed
an increase of LINE-1DNA in the cytoplasmic fraction of RA3331 as com-
pared to RA3331SLX4 (Fig. 3A–B). Interestingly, this observation is con-
comitant to an increase of LINE-1 mRNA as measured by RT-qPCR (Fig.
S3B), suggesting that this DNA accumulation is linked to increased
LINE-1 activity. Indeed, qPCR performed using previously described
primers (Boissinot et al., 2000) that allow the ampliﬁcation of active
LINE-1 (Fig. 3C) and sequencing of obtained PCR products (Fig. S3C)
conﬁrmed the presence of DNA originating from the Ta-1 subfamily of
active LINE-1 elements.
Because SLX4 regulates LINE-1-derived cytoplasmic DNA levels, we
next asked whether the SLX4com interacts with the LINE-1
retrotransposition complex andwhether this interaction is DNA-depen-
dent. LINE-1 expresses a 6 kb bicistronic mRNA encoding two proteins
that are essential for retrotransposition: theORF1p RNA binding protein
and the ORF2pprotein that possess endonuclease and RT activities. Dur-
ing LINE-1 retrotransposition, ORF1p and ORF2p bind to LINE-1 RNA,
forming a ribonucleoprotein particle competent for the reverse tran-
scription of LINE-1 RNA into dsDNA that may integrate into genomic
DNA. Using a previously described LINE-1 reporter construct (LINE-1-
NEO) where the ORF1p protein is C-terminally T7-tagged (Fig. 3D)
(Doucet et al., 2010), we assessed the interaction between SLX4com
and ORF1p. LINE-1-NEO was co-expressed with N-terminally FLAG-
and HA-tagged SLX4 (F/H-SLX4) or SLX4ΔSAP (F/H-SLX4ΔSAP) in
Fig. 2. Cytoplasmic accumulation of ssDNA is responsible for pro-inﬂammatory signals in
SLX4 deﬁciency. (A) Immunoﬂuorescence analysiswas performed onRA3331, RA3331SLX4
and RA3331SLX4ΔSAP using ssDNA-speciﬁc antibody and DAPI nuclear staining. Images are
representative of at least 4 independent experiments. (B) Quantiﬁcation of staining
observed in A. (C) Left panel: experimental scheme. Brieﬂy, cytoplasmic extraction was
performed on RA3331, RA3331SLX4 and RA3331SLX4ΔSAP followed by RNase cocktail
(RNase A and RNase T1) and proteinase K treatments prior to DNA extraction and
radiolabeling. DNA extracted from RA3331 cells was subjected or not to a subsequent S1
Nuclease treatment prior to separation on acrylamide gel and autoradiography. Right
panel: autoradiography of a representative experiment. (D) WCE from RA3331
expressing Luciferase-, MYD88-, or STING-targeting inducible shRNAs were analyzed by
WB using indicated antibodies. (E) Graphs present RT-qPCR quantiﬁcation of knock-
down efﬁciency, measured using speciﬁc primers, as mean (±SD) mRNA expression
relative to cells expressing Luciferase-targeting shRNA from 3 independent experiments.
(F) MxA, RIG-I, TLR4 and TLR2 mRNA levels were measured in cells described in D.
Graphs present means (±SD) of 3 independent experiments as fold increase mRNA
expression relative to cells expressing a Luciferase targeting shRNA. (G) WCE from
RA3331 expressing Luciferase, STING, cGAS or IFI16-targeting inducible shRNAs were
analyzed by WB using indicated antibodies. (H) MxA, STING, cGAS and IFI16 mRNA
levels were measured in cells described in G. Graphs present means (±SD) of 3
independent experiments expressed as fold change in mRNA expression relative to cells
expressing a Luciferase targeting shRNA. ****: p b 0.001; ***: p b 0.005; **: p b 0.01. See
also Fig. S2.
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Input and FLAG-eluted material were analyzed byWB. As shown in Fig.
3E, ORF1p was efﬁciently recovered in F/H-SLX4, but not in F/H-SLX4ΔSAP immunoprecipitation. This shows that SLX4 interacts with
ORF1p through its SAP domain. To explore a potential role of MUS81-
EME1 in this interaction, FLAG-tagged MUS81 (F-MUS81) (Fig. 3F)
was co-expressed with the LINE-1-NEO reporter plasmid in 293T cells.
WCE were subjected to FLAG-immunoprecipitation and the presence
of ORF1p was analyzed by WB. Fig. 3F shows that SLX4, EME1 and
ORF1p were recovered in F-MUS81 immunoprecipitation. To evaluate
the contribution of MUS81-DNA binding domain for interaction with
ORF1p, we used theMUS81ΔWHmutant (Fadden et al., 2013) that har-
bors a deletion of its nucleic acid-binding domain (Fig. 3D). While F-
MUS81ΔWH and F-MUS81 displayed similar ability to interact with
SLX4 and EME1, interaction of F-MUS81ΔWHwith ORF1pwas impaired
(Fig. 3F), showing that interaction of SLX4com with LINE-1 depends on
MUS81 DNA-binding domain. Interestingly, when F-MUS81 immuno-
precipitation was performed in the presence of DNaseI and Ethidium
Bromide (EtBr) that disrupt nucleic acid/protein interactions, MUS81
and ORF1p interaction was lost (Fig. 3G). Altogether, these experiments
show that SLX4com binding to ORF1p is DNA-dependent and requires
MUS81 DNA-binding domain.
We next wished to assess the binding of LINE-1-derived DNA to the
SLX4com. To this aim,we used the LINE-1-GFP reporter plasmid (Fig. 3H
and (Coufal et al., 2009)). In this construct, a green ﬂuorescent protein
(gfp) gene is inserted in the 3′ untranslated region (UTR) of LINE-1 in
antisense orientation relative to LINE-1 expression, under the control
of an independent promoter. The sequence of the gfp is disrupted by
an intronic sequence and GFP expression can only be measured when
the retroelement has undergone a full cycle of retrotransposition, in-
volving transcription, splicing, reverse transcription and integration.
We designed qPCR primers that ﬂank the intronic sequence to discrim-
inate spliced (136 bp) from unspliced LINE-1-derived DNA (Fig. 3H).
This construct was co-expressed in 293T cells together with F/H-SLX4,
F/H-SLX4ΔSAP, F-MUS81 or F-MUS81ΔWH prior to whole cell extrac-
tion and FLAG-immunopuriﬁcation coupled to peptide elution. Efﬁcient
immunoprecipitation of target proteins was veriﬁed by WB (Fig. S3D).
Eluted material was subjected to DNA extraction followed by qPCR.
We observed that LINE-1 DNA was efﬁciently co-immunoprecipitated
with F/H-SLX4 and F-MUS81, but not with SLX4ΔSAP and MUS81ΔWH
(Fig. 3I). We veriﬁed that the ampliﬁed LINE-1 fragment was indeed
136 bp and that similar levels of LINE-1 input material was used (Fig.
S3E–F). Altogether, our observations strongly suggest that the SLX4com
binds to LINE-1 reverse-transcribed DNA via interaction with the
MUS81-EME1 endonuclease module.
Fig. 3.The SLX4com regulates cytoplasmic accumulation of LINE-1DNA. (A) LINE-1DNAwasmeasured byqPCR in the cytoplasmic fraction of RA3331 or RA3331SLX4. #1: primers targeting
the 5′ ofORF1. #2: primers targeting the 3′ ofORF2. (B) CytoplasmicDNA extracted fromRA3331 or RA3331SLX4were analyzedby SouthernBlot using LINE-1 speciﬁc probe. The right panel
shows the molecular weight ladder. (C) Same as in A, except that primers allowing the ampliﬁcation of active LINE-1 elements were used. #3 and #4: primer pairs targeting the 3′ UTR
sequence of LINE-1 Ta-1 sub-family. (D) Constructs used in E-G and I. (E) FLAG/HA-WT-SLX4 or FLAG/HA-SLX4ΔSAP were FLAG-immunoprecipitated from 293T cells in the presence of a
LINE-1-expressing plasmid. Bound material was peptide-eluted. Input and eluates were analyzed by WB using indicated antibodies. (F) FLAG-WT-MUS81 or FLAG-MUS81ΔWHwere
FLAG-immunoprecipitated from 293T cells in the presence of a LINE-1-expressing plasmid. Bound material was peptide-eluted. Input and eluates were analyzed as in E. (G) FLAG-WT-
MUS81 was puriﬁed as in E in the presence or absence of 0.1 mg/ml EtBr and 0.1 U/μl DNaseI. Input and eluates were analyzed as in E. (H) LINE-1 construct used in I. Primers are
indicated in red. (I) FLAG/HA-WT-SLX4, FLAG/HA-SLX4ΔSAP, FLAG-WT-MUS81 or FLAG-MUS81ΔWH were puriﬁed as in E prior to DNA extraction. Samples were analyzed by qPCR
using primers indicated in H. See also Fig. S3.
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We next wished to investigate the consequences of SLX4com bind-
ing to LINE-1 retrotransposition complexes. To this aim, the LINE-1-
NEO reporter construct (Fig. 3D) was transfected in HeLa cells express-
ing empty vector, WT-SLX4 or SLX4ΔSAP. LINE-1-NEO is similar to the
LINE-1-GFP construct, except that the gfp sequence is replaced by a neo-
mycin resistance gene and neomycin resistance arises when the
retroelement has undergone a full retrotransposition cycle. As negative
control, a LINE-1mutant construct unable to perform reverse transcrip-
tion (RT-) was also included in the assay. Crystal violet staining of neo-
mycin-resistant colonies showed that expression ofWT-SLX4, but not of
SLX4ΔSAP (Fig. S4A), decreases the number of colonies as compared to
cells where empty vector was expressed (Fig. 4A). This shows that SLX4is a negative regulator of LINE-1 retrotransposition, a function that re-
quires its SAP domain. We next performed similar experiments except
that we silenced SLX4 or MUS81 using small interfering RNA (siRNA)
prior to transfection of the LINE-1-NEO reporter construct (Fig. 4B and
S4B–C). We observed that absence of SLX4 or MUS81 both lead to in-
creased LINE-1 retrotransposition (Fig. 4B). Finally, to conﬁrm these ob-
servations, we performed retrotransposition assays in RA3331 cell lines.
We used a previously described highly sensitive retrotransposition dual
Luciferase reporter system (Xie et al., 2011) where a Fireﬂy luciferase
(FLuc) gene, disrupted by an intronic sequence, is inserted in the 3′ un-
translated region (UTR) of LINE-1 in antisense orientation relative to
LINE-1 expression, under the control of an independent promoter and
a Renilla luciferase (RLuc) cassette is inserted in the same backbone to
allow for normalization (Fig. 4C). As negative control, a mutant
Fig. 4. The SLX4 complex negatively regulates LINE-1 retrotransposition. (A) LINE-1
retrotransposition assay was performed in HeLa cells overexpressing either WT-SLX4 or
SLX4ΔSAP together with a LINE1-NEO reporter plasmid. Following neomycin selection,
resistant clones were crystal violet stained. Left panel presents one representative
experiment. Graph represents crystal violet staining quantiﬁed over 3 independent
experiments relative to cells expressing an empty vector. (B) LINE-1 retrotransposition
assay was performed as in A, except that HeLa cells were treated with scrambled siRNA
or siRNAs targeting SLX4 or MUS81. Graphs represent quantiﬁcation as in A. (C) LINE-1
constructs used in D. LINE-1-ORF1mut contains the JM111 mutation in the ORF1
sequence that abolishes retrotransposition. (D) LINE-1 retrotransposition assay
performed in RA3331 or RA3331SLX4 transfected with plasmids described in C. Means
(±SD) Luciferase activity of triplicate measurement from 4 independent experiments is
presented as a percentage of maximum signal intensity. ****: p b 0.001. See also Fig. S4.
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ed in the assay (Fig. 4C). These constructs were transfected in RA3331
and RA3331SLX4 cells and retrotransposition efﬁciency was quantiﬁed
as the ratio of FLuc/RLuc. We thereby observed that complementing
the RA3331 cells with WT-SLX4 caused a 2.5 fold decrease in the mea-
sured Luciferase activity (Fig. 4D), reﬂecting decreased ability of LINE-1 to retrotranspose in the presence of WT-SLX4. Of note, to control
whether sole expression of SLX4 could affect the expression of a neomy-
cin resistance gene, we transfected a shRNA containing a neomycin re-
sistance gene in HeLa cells expressing empty vector or WT-SLX4. After
crystal violet staining, we observed that overexpression of SLX4 does
not decrease the expression of neomycin resistance gene (Fig. S4D).
We next wanted to assess whether LINE-1 regulation is speciﬁc to
the SLX4com or is a general function for the FA DNA repair pathway.
To this aim, we tested the role of FANCD2 and FANCA in regulating
LINE-1 retrotransposition. FANCD2 exerts a crucial role by orchestrating
the activation of downstream effectors of the FA DNA repair pathway,
including SLX4, while FANCA is a component of the FA core complex re-
sponsible of the activation of FANCD2-FANCI (Longerich et al., 2014).
Retrotransposition assays using the LINE-1-NEO reporter plasmid in
the presence or absence of siRNAs targeting FANCD2 or FANCA (Fig.
5A, S5A–B) showed that their absence leads to increased LINE-1
retrotransposition. We next investigated whether absence of FANCD2
also leads to cytokine upregulation. To this aim, we measured IFNα,
IFNβ, IFNγ and MxA mRNA levels by RT-qPCR in FANCD2-deﬁcient or
proﬁcient cells. We observed that FANCD2-deﬁcient cells, produced
type I IFN, type II IFN and MxA mRNA as compared to their WT-
FANCD2-complemented counterparts (Fig. 5B). In agreement, immuno-
ﬂuorescence analysis of cytoplasmic ssDNA content, revealed the accu-
mulation of ssDNA in the cytoplasm of FANCD2-deﬁcient cells, as
compared to their WT-FANCD2 complemented counterparts (Fig. 5C,
S5C). Importantly, as in SLX4-deﬁcient cells, we observed that this spon-
taneous production of cytokines relies on the cGAS-STING pathway (Fig.
5D–E). Altogether, our data demonstrate a correlation between absence
of a functional FADNA repair pathway, elevatedpro-inﬂammatory cyto-
kine production through activation of the cGAS-STING pathway (Figs. 2
and 5) and upregulated LINE-1 activity (Figs. 4 and 5).
3.4. Endogenous Reverse Transcriptase Activities Contribute to Generate
Immunogenic Nucleic Acid Species
Our observations suggest a correlation between upregulated LINE-1
activity and increased cytokine production in FA. To further strengthen
this correlation, we determined the effect of the Tenofovir (TenoF) nu-
cleoside analogue RT inhibitor, known to prevent LINE-1
retrotransposition (Jones et al., 2008), on IFN production in FA. Treat-
ment of RA3331 with TenoF, at doses known to inhibit LINE-1
retrotransposition (Fig. S6A), showed signiﬁcant decrease of IFNα,
IFNβ, IFNγ andMxAmRNA levels (Fig. 6A). Similar results were obtain-
ed with FANCD2-deﬁcient cells (Fig. 6B). This indicates that inhibiting
endogenous RT activities prevents spontaneous pro-inﬂammatory cyto-
kine production in FA-derived cells. This further suggests that in FA, un-
controlled retrotransposition may be a source of immunogenic nucleic
acids. To test this hypothesis, DNA was extracted from the cytoplasmic
fraction of RA3331 cells treated or not with TenoF prior to radiolabeling
(Fig. 6C) or qPCR using LINE-1-speciﬁc primers (Fig. 6D). We thus ob-
served that such treatment caused a decrease of both total cytoplasmic
and LINE-1-derived DNA.
It has been shown that DNA damage-inducing agents, including the
Cisplatin (CisP) DNA crosslinker, can induce LINE-1 activation (Rudin
and Thompson, 2001). Thus, we tested the impact of DNA damage-in-
ducing agents, such as CisP, MMC and hydroxyurea (HU), on the activa-
tion of pro-inﬂammatory pathways (Fig. 6E–F and S6B–C).We observed
that CisP treatment caused increased IFNα, IFNβ, IFNγ and MxA mRNA
levels and pIRF3 accumulation, which was prevented by treatment of
cells with TenoF 24 h prior to CisP treatment (Fig. 6E–F). Of note, similar
observations were made upon treatment with MMC and HU (Fig. S6B–
C). To exclude that TenoF treatment would affect the ability of CisP,
MMC and HU to cause DNA lesions, we assessed CHK1 phosphorylation
status. Indeed, the CHK1 kinase becomes activated via phosphorylation
upon replication stress, as induced by treatment with CisP, MMC and
HU. We observed that TenoF treatment marginally affected CHK1
Fig. 5. Absence of FANCD2 leads to upregulated STING-dependent IFN production. (A)
Retrotransposition was measured and results presented as in Fig. 4A except that cells
were treated with scrambled siRNA or siRNA targeting FANCD2. (B) IFNα, IFNβ, IFNγ
and MxA mRNA levels were measured in FANCD2 deﬁcient cells and on their WT-
FANCD2 complemented counterparts. Graphs present means (±SD) from triplicate
measurement of 6 independent experiments expressed as fold mRNA expression
relative to FANCD2 proﬁcient cells. (C) Immunoﬂuorescence was performed on FANCD2
deﬁcient or proﬁcient cells as in Fig. 2A. (D) WCE from PD20 expressing Luciferase,
STING, cGAS or IFI16-targeting inducible shRNAs were analyzed by WB using indicated
antibodies. (E) MxA, STING, cGAS and IFI16 mRNA levels were measured in cells
described in D. Graphs present means (±SD) of 4 independent experiments expressed
as fold change in mRNA expression relative to cells expressing Luciferase targeting
shRNA. ****: p b 0.001; ***: p b 0.005; **: p b 0.01. See also Fig. S5.
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did not signiﬁcantly affect pCHK1 and SLX4 expression levels (Fig. S6D–
E). This implies that TenoF inhibits activation of pro-inﬂammatory path-
ways triggered by tested DNA damage inducing drugs, independently
from their ability to cause DNA lesions. Of note, we also observed that
TenoF treatment weakly affected DNA crosslink- and cytokine-associated cell death of RA3331 cells (Fig. S6F–G). Thus, altogether,
our observations strongly suggest that DNA damaging agents cause ac-
tivation of pro-inﬂammatory pathways through endogenous reverse
transcriptase activity including that of LINE-1.
4. Discussion
Chronic inﬂammation that fosters a favorable environment for
tumor initiation can be generated by both cell-extrinsic and cell-intrin-
sic factors. The latter include inability to repair genomic lesions (Rodier
et al., 2009; Zheng et al., 2007). Indeed, recent work has provided evi-
dence for the implication of DDR pathways in the regulation of sponta-
neous and pathogen-induced innate immune responses (Bregnard et
al., 2014). However, there is as of today poor understanding of the un-
derlying molecular mechanisms. Here we used FA as a model cancer
susceptibility syndrome to investigate the origins of chronic inﬂamma-
tion. We show that elevated pro-inﬂammatory cytokine production in
the absence of a functional FA DNA repair pathway results, at least in
part, from upregulated LINE-1 activity. In this model, we observed that
absence of SLX4 leads to upregulated LINE-1 retrotransposition, accu-
mulation of immunogenic cytoplasmic DNA comprising active LINE-1-
derived sequences and concomitant up-regulated pro-inﬂammatory cy-
tokine production. This is further supported by the witnessed physical
interaction between the SLX4com and the LINE-1 retrotransposition
complex and decreased pro-inﬂammatory cytokine production upon
RT inhibitor treatment. In addition, in SLX4-deﬁcient cells, LINE-1 tran-
scription and retrotransposition are increased and thenucleoplasmcon-
tains immunogenic nucleic acids that may subsequently be exported to
the cytoplasm and recognized by the cGAS-STING pathway to induce
pro-inﬂammatory cytokine production (Fig. 7). Requirement of cGAS
for activation of pro-inﬂammatory pathways in these cells suggests
that dsDNA species are involved in the signaling cascade. However,
since we also observed the accumulation of ssDNA and DNA:RNA hy-
brids, one can speculate that such nucleic acid speciesmay either be rec-
ognized by the same pathway, or by additional yet to be identiﬁed
pathways. Moreover, additional transposable elements detected by
the cGAS-STING pathwaymay induce IFN production in SLX4 deﬁciency
(Zeng et al., 2014). Interestingly, it has also been reported that tumor-
derived DNA can activate the STING pathway in innate immune cells
within the tumor microenvironment (Woo et al., 2014) and that a
STING-dependent mechanism is involved in the induction of an adap-
tive immune response following radiation (Deng et al., 2014). It would
thus be interesting to investigate the inﬂuence of SLX4-deﬁcient cells-
derived DNA on adaptive immune responses.
FA presents with progressive bonemarrow failure, increased cancer
susceptibility and elevated pro-inﬂammatory cytokine production. FA-
associated bone marrow failure has been shown to, at least in part, re-
sult from exhaustion of chronic cytokine-stimulation of bone marrow-
resident stem cells (Garaycoechea and Patel, 2014). While deregulated
cytokine production contributes to these bonemarrow-related hemato-
logical dysfunctions, it is possible that persistent secretion of IFN can
also contribute to the advent of malignancies in FA. Here we show
that SLX4 and its upstream activator FANCD2 directly repress LINE-1
retrotransposition and prevent accumulation of cytoplasmic nucleic
acids. This suggests that the FA DNA repair pathway as a whole may
be involved in regulating LINE-1 activity and subsequent pro-inﬂamma-
tory cytokine production. This further implies that upregulated LINE-1
retrotransposition occurs in FA patients and that LINE-1 activity may
play an important role in the advent of clinical manifestations of FA.
This is particularly important because of the pivotal role of FANCD2 in
the activation of the FA DNA repair pathway.
We also show that recruitment of MUS81-EME1 is required for
SLX4com-mediated control of pro-inﬂammatory signaling. This sug-
gests that, similar to what was previously reported for HIV biology
(Laguette et al., 2014), the SLX4com likely represses LINE-1
retrotransposition through the endonucleolytic action of MUS81-
Fig. 6. Upregulated retrotransposition leads to pro-inﬂammatory signaling. (A) IFNα, IFNβ, IFNγ and MxA mRNA levels were measured in RA3331 cells following 48 h treatment with
125 μM TenoF. Graphs present means (±SD) from triplicate measurement of 6 independent experiments expressed as fold change in mRNA expression relative to RA3331. ****:
p b 0.001; ***: p b 0.005; **: p b 0.01. (B) IFNα, IFNβ, IFNγ and MxA mRNA levels were measured in FANCD2-deﬁcient cells following 48 h treatment with 5 μM TenoF. Graphs present
means (±SD) from triplicate measurement of 6 independent experiments expressed as fold change in mRNA expression relative to untreated cells. ****: p b 0.001; ***: p b 0.005; **:
p b 0.01. (C) Cytoplasmic DNA was prepared from RA3331 cells following 8 h treatment with 125 μM TenoF, radiolabeled and analyzed by autoradiography. (D) DNA was prepared as
described in C and analyzed by qPCR using primers described in Fig. 3A. Graph presents data from a representative experiment. (E) IFNα, IFNβ, IFNγ and MxA mRNA levels were
measured in RA3331SLX4 treated or not with 125 μM TenoF 24 h prior to treatment with 10 μM Cisplatin. Graphs present means (±SD) from 3 independent experiments as fold
change in mRNA expression, relative to untreated cells. ****: p b 0.001; ***: p b 0.005; **: p b 0.01; *: p b 0.05. (F) WCE from cells treated as in E were analyzed by WB. See also Fig. S6.
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within the SLX4com, PLK1-dependent EME1 hyperphosphorylation is
required, which occurs around the G2/M boundary. It would thus be
interesting to investigate whether the control of endogenous
retroelements mobility and the ability to repress pro-inﬂammatoryFig. 7. Inhibition of LINE-1 retrotransposition by the SLX4com prevents pro-inﬂammatory sign
reverse transcribed LINE-1 DNA. LINE-1-derived DNA are likely subsequently degraded. (B) In
the cytoplasm. These are recognized by the cGAS-STING pathway to activate pro-inﬂammato
DNA.cytokine production depend on the cell cycle status. Additional post-
translational modiﬁcations, such as SUMOylation and PARylation,
were recently shown to be required for SLX4 activity by ensuring its lo-
calization to sites of DNA damage (Gonzalez-Prieto et al., 2015;
Guervilly et al., 2015; Ouyang et al., 2015). Requirement for such post-aling. (A) The SLX4com inhibits LINE-1 retrotransposition by preventing accumulation of
the absence of the SLX4com, by-products of LINE-1 reverse-transcription accumulate in
ry signaling. Grey lines represents: LINE-1 RNA; green lines: LINE-1 reverse-transcribed
193C. Brégnard et al. / EBioMedicine 8 (2016) 184–194translational modiﬁcations in the recognition and processing of poten-
tial immunogenic nucleic acids remains to be investigated.
Interestingly, it has been previously reported that the bone marrow
of FA patients is compromised because of accumulation of DNA damage
in hematopoietic stem cells (Ceccaldi et al., 2012). Our ﬁndings imply
that this may also be linked to upregulated LINE-1 activity. Indeed,
LINE-1mobility is mostly repressed in cells through 5′UTRmethylation
(Woodcock et al., 1997; Yu et al., 2001) and stem cells have a
hypomethylated genome that allows enhanced LINE-1 activity
(Wissing et al., 2012). Thus, absence of the FA pathway may also allow
for pro-tumorigenic LINE-1 re-insertion events, especially in the light
of the LINE-1 DNAderiving from themost active LINE-1 subfamily accu-
mulating in the cytoplasm of SLX4-deﬁcient cells. This raises the possi-
bility that treatment with RT inhibitors, which inhibit the accumulation
of immunogenic nucleic acids responsible for initiating pro-inﬂamma-
tory cytokines production, may delay or prevent the onset of bonemar-
row failure in FA. In support, immunotherapy aiming at neutralizing a
single pro-inﬂammatory cytokine (TNFα) has shown promising posi-
tive effects in patients (Mehta et al., 2012;Miehsler et al., 2010). Accord-
ingly, we observed that treatmentwith TenoFweakly decreased the cell
death of SLX4-deﬁcient cells following treatment with TNFα or DNA
damaging drugs. Of note, bone marrow failure is a clinical trait shared
by additional familial cancer susceptibility syndromes (Parikh and
Bessler, 2012) that could also be linked to deregulated endogenous RT.
Finally, the key role played by chronic inﬂammation in the progres-
sion of cancer is highlighted by the fact that anti-inﬂammatory drugs
when administered to patients can reduce the risk of progression tome-
tastasis (Markowitz, 2007). One interesting ﬁnding from our work is
that treatmentwith TenoF prevents inﬂammation caused by DNA-dam-
aging agents such as those used in chemotherapy. This is of particular
importance because it has been reported that treatment with chemo-
therapy may generate a pro-inﬂammatory environment that would se-
lect cells that are resistant to treatment (de Visser and Jonkers, 2009;
Koti et al., 2015). Our data conﬁrm the previous observation that certain
DNA-damage inducing drugs can cause LINE-1 reactivation (Rudin and
Thompson, 2001) and enforce the contribution of endogenous RT activ-
ities to inﬂammation. Furthermore, we observed a weak but reproduc-
ible decrease of pCHK1 levels in cells treated with RT inhibitors in the
presence of DNA-damaging drugs. This is in agreement with previous
reports of LINE-1 activity poising a mutagenic threat to the genome be-
cause of their ability to integrate at distant genomic locations. Thus, al-
together our in vitro observations suggest that combination of
chemotherapy with RT inhibitors could prevent the establishment of
an inﬂammatory tumor microenvironment that would favor
chemoresistance and decrease the risk of genomic instability. Thus,
our study may open perspectives for the treatment of FA patients but
also for reducing adverse effects of chemotherapy.
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